Alder Biopharmaceuticals, the Bothell, WA-based developer of antibody drugs, said today it has added veteran drug developer Bruce Montgomery to its board of directors. Montgomery, 57, most recently served as senior vice president of respiratory drugs at Gilead Sciences (NASDAQ: [[ticker:GILD]]) in Seattle. Montgomery stepped down from Gilead in August to look for new opportunities, and last month he joined the board of Seattle-based Geospiza. Alder, which was profiled in Xconomy in January, is seeking to use a yeast-based technology that it hopes will provide a faster, cheaper method for creating targeted antibody drugs against cancer and autoimmune diseases
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
